Photocure ASA (PHCUF) has released an update.
Photocure ASA has announced that its partner, Asieris Pharmaceuticals, will present Phase III clinical trial data for the non-surgical cervical HSIL treatment, Cevira (APL-1702), at a conference in Germany. The trial met its primary efficacy endpoint and showed a higher regression rate in the treatment group compared to placebo. Cevira is a photodynamic drug-device combination product that has shown promise in treating high-grade squamous intraepithelial lesions without surgery.
For further insights into PHCUF stock, check out TipRanks’ Stock Analysis page.
